VEA vs XBI
Vanguard FTSE Developed Markets ETF vs SPDR S&P Biotech ETF
- • VEA has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VEA pays a higher dividend yield (2.54%).
Side-by-side metrics
| Metric | VEA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.54% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $316.31B | $10.73B |
YTD return | 13.38% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.97 | 1.10 |
P/E ratio | 18.29 | — |
Last price | $70.92 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
VEA top holdings
| 005930.KS | Samsung Electronics Co Ltd | 3.01% |
| 000660.KS | SK Hynix Inc | 2.57% |
| ASML.AS | ASML Holding NV | 1.91% |
| HSBA.L | HSBC Holdings PLC | 0.98% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 0.90% |
| NOVN.SW | Novartis AG Registered Shares | 0.88% |
| AZN.L | AstraZeneca PLC | 0.85% |
| RY | Royal Bank of Canada | 0.82% |
| NESN.SW | Nestle SA | 0.80% |
| SHEL.L | Shell PLC | 0.73% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About VEA
VEA (Vanguard FTSE Developed Markets ETF) is Developed-market stocks outside the US and Canada. Managed by Vanguard, the fund carries $316.3B in assets under management, an expense ratio of 0.03%, a dividend yield of 2.54%. Its largest holding is Samsung Electronics Co Ltd (005930.KS), which represents 3.0% of the portfolio. Real Estate is the fund's largest sector exposure at 2.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.